Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah Blagden

Showing results (11-20 of 35) with videos related to

Pageof 4
Sort By:
Women'S Health (London, England)|June 24, 2015
The next steps in improving the outcomes of advanced ovarian cancerMark R Openshaw, Christina Fotopoulou, Sarah Blagden, et al.
European Journal of Cancer (Oxford, England : 1990)|November 18, 2005
Making sense of antisenseLaura Vidal, Sarah Blagden, Gerhardt Attard, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 9, 2013
Feasibility of trials in ovarian cancer by line of therapy and platinum sensitivityRoekshana Shaboodien, Nikolaos Diamantis, Sarah Blagden, et al.
Bjpsych Bulletin|September 23, 2020
A qualitative exploration of the barriers to and facilitators of clozapine monitoring in a secure psychiatric settingSarah Blagden, Jane Beenstock, Natalie Auld, et al.
Gastroenterology Nursing : the Official Journal of the Society of Gastroenterology Nurses and Associates|July 31, 2015
A Comparative Study of Quality of Life in Persons With Irritable Bowel Syndrome and Inflammatory Bowel DiseaseSarah Blagden, Thomas Kingstone, Andrew Soundy, et al.
Gynecologic Oncology|December 14, 2011
A study of symptoms described by ovarian cancer survivorsChara Stavraka, Amy Ford, Sadaf Ghaem-Maghami, et al.
Oncotarget|February 1, 2012
Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancerHelen M Coley, Eleftheria Hatzimichael, Sarah Blagden, et al.
BMJ Open|August 2, 2022
Interventions delivered in secondary or tertiary medical care settings to improve routine vaccination uptake in children and young people: a scoping reviewSarah Blagden, Kathryn Newell, Nareh Ghazarians, et al.
Journal of Medicinal Chemistry|January 30, 2014
Application of ProTide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical developmentMagdalena Slusarczyk, Monica Huerta Lopez, Jan Balzarini, et al.
Ebiomedicine|January 9, 2026
The circulating proteome and cancer risk: a systematic literature review and meta-analysis of 26 prospective studies with genetic validationAlison Dillman, Haige An, Zhe Huang, et al.
Pageof 4

Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Women'S Health (London, England)|June 24, 2015
The next steps in improving the outcomes of advanced ovarian cancerMark R Openshaw, Christina Fotopoulou, Sarah Blagden, et al.
European Journal of Cancer (Oxford, England : 1990)|November 18, 2005
Making sense of antisenseLaura Vidal, Sarah Blagden, Gerhardt Attard, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 9, 2013
Feasibility of trials in ovarian cancer by line of therapy and platinum sensitivityRoekshana Shaboodien, Nikolaos Diamantis, Sarah Blagden, et al.
Bjpsych Bulletin|September 23, 2020
A qualitative exploration of the barriers to and facilitators of clozapine monitoring in a secure psychiatric settingSarah Blagden, Jane Beenstock, Natalie Auld, et al.
Gastroenterology Nursing : the Official Journal of the Society of Gastroenterology Nurses and Associates|July 31, 2015
A Comparative Study of Quality of Life in Persons With Irritable Bowel Syndrome and Inflammatory Bowel DiseaseSarah Blagden, Thomas Kingstone, Andrew Soundy, et al.
Gynecologic Oncology|December 14, 2011
A study of symptoms described by ovarian cancer survivorsChara Stavraka, Amy Ford, Sadaf Ghaem-Maghami, et al.
Oncotarget|February 1, 2012
Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancerHelen M Coley, Eleftheria Hatzimichael, Sarah Blagden, et al.
BMJ Open|August 2, 2022
Interventions delivered in secondary or tertiary medical care settings to improve routine vaccination uptake in children and young people: a scoping reviewSarah Blagden, Kathryn Newell, Nareh Ghazarians, et al.
Journal of Medicinal Chemistry|January 30, 2014
Application of ProTide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical developmentMagdalena Slusarczyk, Monica Huerta Lopez, Jan Balzarini, et al.
Ebiomedicine|January 9, 2026
The circulating proteome and cancer risk: a systematic literature review and meta-analysis of 26 prospective studies with genetic validationAlison Dillman, Haige An, Zhe Huang, et al.
Pageof 4